Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Antiviral Treatment in HBeAg Positive CHB
NCT03013556Phase 4Unknown
- Sponsor
- Ruijin Hospital
- Start
- Nov 2016
- Primary completion
- Dec 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03013556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013556.